Acumen first participant dosed in OLE portion of Phase 2 ALTITUDE-AD trial

Acumen (ABOS) Pharmaceuticals announced that the first participant has been dosed in the open-label extension, OLE, portion of its Phase 2 ALTITUDE-AD clinical trial evaluating sabirnetug in people with early Alzheimer’s disease. The open-label extension provides all participants who completed the 18-month placebo-controlled portion of ALTITUDE-AD with the opportunity to receive sabirnetug at 35 mg/kg administered intravenously once every four weeks for an additional 52 weeks. Clinical measures and safety monitoring will be the same as in the placebo-controlled portion of the study.